Doliver Advisors, LP
- SEC CIK
- 0000938077
- Latest filing
- Oct 1, 2026
BCRX holding history
Biocryst Pharmaceuticals Inc in every 13F filed by Doliver Advisors, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BCRX overviewAll 13F holders of BCRXFull Q3 2026 holdings
- Shares (Q3 2026)
- 304,328
- Value
- $2.54M
- % of portfolio
- 0.6%
- Quarters held
- 21
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2026 | 304,328 | $2.54M | 0.6% | −70,000−18.7% | Reduced | Holders |
| Q2 2026 | 374,328 | $3.74M | 0.8% | 00.0% | Unchanged | Holders |
| Q1 2026 | 374,328 | $3.56M | 0.8% | +100,000+36.5% | Added | Holders |
| Q4 2025 | 274,328 | $2.14M | 0.5% | 00.0% | Unchanged | Holders |
| Q3 2025 | 274,328 | $2.08M | 0.5% | 00.0% | Unchanged | Holders |
| Q2 2025 | 274,328 | $2.46M | 0.7% | +200,000+269.1% | Added | Holders |
| Q1 2025 | 74,328 | $557.5K | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2024 | 74,328 | $558.9K | 0.2% | −6,672−8.2% | Reduced | Holders |
| Q3 2024 | 81,000 | $615.6K | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2024 | 81,000 | $500.6K | 0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 81,000 | $411.5K | 0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 81,000 | $485.2K | 0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 81,000 | $573.5K | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2023 | 81,000 | $570.2K | 0.2% | 00.0% | Unchanged | Holders |
| Q1 2023 | 81,000 | $675.5K | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2022 | 81,000 | $929.9K | 0.3% | 00.0% | Unchanged | Holders |
| Q3 2022 | 81,000 | $1.02M | 0.4% | 00.0% | Unchanged | Holders |
| Q2 2022 | 81,000 | $857.0K | 0.3% | 00.0% | Unchanged | Holders |
| Q1 2022 | 81,000 | $1.32M | 0.4% | −19,000−19.0% | Reduced | Holders |
| Q4 2021 | 100,000 | $1.52M | 0.5% | 00.0% | Unchanged | Holders |
| Q3 2021 | 100,000 | $1.44M | 0.5% | +100,000 | New | Holders |